Pharma News

The Central Government has officially amended the Drugs Rules, 1945, allowing Navi Mumbai Airport to be used as an authorized entry point for the import of drugs into India. The amendment has been notified through the Drugs (Ninth Amendment) Rules, 2026, which came into force upon its publication in the Official Gazette.

Marksans Pharma Ltd. has announced the acquisition of 100% share capital of ABCnow GmbH, a Germany-based pharmaceutical wholesale and distribution company, in a strategic move to strengthen its presence across regulated European markets. The company has entered into a definitive agreement to acquire the business as part of its forward integration strategy.

The acquisition will be completed through a cash consideration of €892,384, with the transaction expected to close by July 31, 2026. Marksans stated that no government or regulatory approvals are required for the acquisition.

The U.S. Food and Drug Administration (FDA) has approved Trutakna (atacicept-vymj) to reduce proteinuria (excess protein in the urine) in adults with primary Immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. The approval provides a new treatment option for patients with this rare kidney disease, which can eventually lead to kidney failure.

Researchers have identified critical antibody binding sites on the JC polyomavirus (JCPyV), a breakthrough that could pave the way for the first effective treatments and vaccines against the virus responsible for progressive multifocal leukoencephalopathy (PML), a rare but usually fatal brain disease affecting people with severely weakened immune systems. The findings were published in the journal PNAS.

Researchers have uncovered a key biological mechanism that explains why muscles become weaker with age and why regular exercise remains one of the most effective ways to preserve muscle strength. The findings identify a gene called DEAF1 as a major driver of age-related muscle decline and suggest it could become a promising target for future therapies.

Vertex Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of CASGEVY (exagamglogene autotemcel), allowing its use in children 2 years of age and older with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises (VOCs) and transfusion-dependent beta thalassemia (TDT). The therapy was previously approved only for patients aged 12 years and older.

Glenmark Pharmaceuticals Inc., USA, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the United States. The newly launched product is bioequivalent and therapeutically equivalent to Zyprexa® IntraMuscular Injection 10 mg/vial (NDA 021253) marketed by Cheplapharm Registration GmbH.